Nexalin Technology (NASDAQ: NXL) has announced the appointment of Robert DiTota as senior strategic advisor, global commercialization, effective September 15, 2026.
Mr. DiTota brings more than 20 years of neuroscience and medical device sales experience and will work directly with Nexalin’s executive management team and board of directors to advise on commercial strategy, international distribution and market development plan, go-to-market approach, and the commercial infrastructure and organizational development needed to support distribution of its neurostimulation platform.
In a statement, Mark White, president and CEO of Nexalin, commented, “The clinical and regulatory work of the past several years is what makes this next phase possible. We have approvals in four countries and a growing body of published data behind the technology. What we need to build now is the commercial organization that turns that into sales. Rob has spent his career doing exactly that in neuromodulation, at Abbott and at Medtronic, in the U.S. He understands how these products reach physicians and patients, how distribution partners are selected and held accountable, and what has to be in place before a launch. We are fortunate to have him working alongside us as we make this transition.”
